• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mapping Fact-P To EQ-5D In Metastatic Castration-Resistant Prostate Cancer (MCRPC): Performance Of A Previously Developed Algorithm When Applied On A Sample With A Different Disease Stage.

作者信息

Ivanescu C, Longworth L, Skaltsa K, Holmstrom S

机构信息

Quintiles Consulting, Hoofddorp, The Netherlands.

Brunel University, Uxbridge, UK.

出版信息

Value Health. 2014 Nov;17(7):A567. doi: 10.1016/j.jval.2014.08.1890. Epub 2014 Oct 26.

DOI:10.1016/j.jval.2014.08.1890
PMID:27201884
Abstract
摘要

相似文献

1
Mapping Fact-P To EQ-5D In Metastatic Castration-Resistant Prostate Cancer (MCRPC): Performance Of A Previously Developed Algorithm When Applied On A Sample With A Different Disease Stage.转移性去势抵抗性前列腺癌（MCRPC）中事实-P与EQ-5D的映射：将先前开发的算法应用于不同疾病阶段样本时的性能
Value Health. 2014 Nov;17(7):A567. doi: 10.1016/j.jval.2014.08.1890. Epub 2014 Oct 26.
2
Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate cancer.将 FACT-P 映射到转移性去势抵抗性前列腺癌的偏好加权 EQ-5D 问卷中。
Value Health. 2014 Mar;17(2):238-44. doi: 10.1016/j.jval.2013.12.005.
3
Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC).瑞典使用新的EQ-5D值集进行成本效用分析的结果与启示。恩杂鲁胺（Xtandi®）对比最佳支持治疗用于转移性去势抵抗性前列腺癌（MCRPC）治疗的应用。
Value Health. 2014 Nov;17(7):A648. doi: 10.1016/j.jval.2014.08.2350. Epub 2014 Oct 26.
4
Comparison of FACT- and EQ-5D-based utility scores in cancer.癌症患者 FACT 和 EQ-5D 量表效用评分的比较。
Value Health. 2012 Mar-Apr;15(2):305-11. doi: 10.1016/j.jval.2011.11.029. Epub 2012 Feb 2.
5
Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients.将FACT-P和EORTC QLQ-C30映射到通过EQ-5D测量的转移性激素难治性前列腺癌患者的健康状况。
Value Health. 2007 Sep-Oct;10(5):408-14. doi: 10.1111/j.1524-4733.2007.00195.x.
6
Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer.前列腺癌正在发生变化吗？：转移性去势抵抗性前列腺癌的演变模式
Cancer. 2014 Mar 15;120(6):833-9. doi: 10.1002/cncr.28494. Epub 2013 Dec 30.
7
Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.多西他赛和阿比特龙在转移性去势抵抗性前列腺癌男性患者中的最佳给药顺序
Prostate. 2015 Nov;75(15):1814-20. doi: 10.1002/pros.23064. Epub 2015 Aug 26.
8
Mapping the English and Chinese versions of the Functional Assessment of Cancer Therapy-General to the EQ-5D utility index.将癌症治疗功能评估通用量表的英文和中文版本映射到 EQ-5D 效用指数。
Value Health. 2009 Mar-Apr;12(2):371-6. doi: 10.1111/j.1524-4733.2008.00448.x. Epub 2008 Sep 9.
9
Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer.合并 Charlson 共病指数和高血压与转移性去势抵抗性前列腺癌男性患者生存的关系。
Urol Oncol. 2014 Jan;32(1):36.e27-34. doi: 10.1016/j.urolonc.2013.02.015. Epub 2013 May 16.
10
Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger.当代一系列年龄在60岁及以下的去势抵抗性前列腺癌“年轻”患者的临床结局。
Urol Oncol. 2015 Jun;33(6):265.e15-21. doi: 10.1016/j.urolonc.2015.02.016. Epub 2015 Apr 20.

引用本文的文献

1
Combined cancer patient-reported symptom and health utility tool for routine clinical implementation: a real-world comparison of the ESAS and EQ-5D in multiple cancer sites.用于常规临床实施的癌症患者报告症状和健康效用联合工具：多个癌症部位的 ESAS 和 EQ-5D 的真实世界比较。
Curr Oncol. 2019 Dec;26(6):e733-e741. doi: 10.3747/co.26.5297. Epub 2019 Dec 1.